3rd Antigen Specific Immune Tolerance Summit

Accelerate the progression of ethical and effective antigen specific immunotherapies through the clinic, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies.Building on the success of the 2019 meeting, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27, 2020. The meeting will bring together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.
 

Speakers: 
Kurt Griffin , Associate Professor, University of South Dakota Sanford School of Medicine, Andreas Lutterotti , Head of Experimental Therapies Research , University Hospital Zurich, Stephen Miller, Co-Founder of Cour Pharmaceuticals; Professor of Microbiology- Immunology, Northwestern University Medical School, Aaron Michels  Associate Professor of Pediatrics Medicine, and Immunology, Barbara Davis Center for Diabetes, University of Colorado; Chief Scientific Officer  IM Therapeutics, Shahrokh Shabahang , Chief Innovation Officer, AdiTxt Therapeutics, Kei Kishimoto , Chief Scientific Officer, Selecta Biosciences, David Alleva , Executive Director, Akston Biosciences, Giles Benichou , Associate Professor of Surgery, Harvard Medical School, Senior Immunologist  Massachusetts General Hospital, Emilio Flano, Director and Head of Immunology Discovery , Merck and Co, Matthias von Herrath , Vice President,  Novo Nordisk, Martin Roland, Head - Department of Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Dolly Tyan  Professor, Emerita of Pathology  Stanford, University School of Medicine, Lawrence Steinman, Professor of Neurology, Neurological Sciences and Pediatrics, Stanford University, Anne De Groot  Founder, Chief Executive Officer and Chief Scientific Officer, Epivax, Ben Williams, Program Officer for the Type 1 Diabetes (T1D) Program, Helmsley Charitable Trust, Giorgio Raimondi, Associate Scientific Director for Transplant Immunology , John Hopkins School of Medicine, Cory Berkland, Distinguished Professor, School of Pharmacy Pharmaceutical Chemistry, University of Kansas, Todd Zion, President and Chief Executive Officer, Akston Biosciences, Garth Ringheim, Director Immunology Therapeutic Area, Clarivate Analysis, Curtis Ruegg, President and Chief Executive Officer, Parvus Therapeutics, Inc., Jack Ragheb, Senior Medical Fellow for Immunology in Global Patient Safety, Eli Lilly and Co., Arpita Maiti, Executive Director and Global Head, Global Head Pfizer, Kristina M. Harris  Director, Biomarker and Discovery Research, Immune Tolerance Network, Joshua Sestak, President and Chief Executive Officer, Founder  Orion BioScience, Monali Manohar, Life Science Research Scientist  Stanford, University School of Medicine, Colin Dayan, Professor of Clinical Diabetes and Metabolism  Cardiff, University School of Medicine, David Wraith, Director of the Institute of Immunology and Immunotherapy , University of Birmingham, Stephan Kontos, Founder and Chief Scientific Officer, Anokion, Simi Ahmed, Director of Research and Lead of the Immune Therapies Program, JDRF, Waldo Concepcion,  Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Nephrology), Stanford University Medical Center, Amy Rosenberg, Director - Therapeutic Proteins and CDER, FDA

Others Details

Time: 9:00 am - 6:00 pm